Open-Label, Phase 1 Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2015
At a glance
- Drugs APTO 253 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors Lorus Therapeutics
- 24 Feb 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
- 01 Oct 2013 Results have been presented at the 2013 European Cancer Congress annual meeting according to a Lorus Therapeutics media release. Results were also summarised in the media release.
- 09 Jul 2013 Promising results reported in a Lorus Therapeutics media release.